AMC's "Record Revenue" Is Real. So Is the Printing Press.

# AMC's "Record Revenue" Is Real. So Is the Printing Press.

Let's start with the number that actually matters: 105.3 million. That's roughly how many new shares AMC sold in a single at-the-market raise back in June, on top of a $200 million registered direct offering that closed June 25. Two capital raises, one month, north of $350 million combined. If you're an existing shareholder, that's not a footnote — that's the whole plot.

Now, the bull case isn't nothing. AMC's Q2 2026 print, reported July 20, showed record top-line revenue with what's being called "massive operating leverage" — the kind of phrase that sounds great until you scroll down and see the GAAP losses are still there, stubborn as ever. This isn't a new script. Q1 2026 already showed the pattern: revenue up 21.2% year-over-year against expense growth of just 3.6%, which narrowed the operating loss from $145.9 million to $45.7 million. That's genuine progress on the cost side. Per-patron economics are hitting records too — $12.25 in admissions revenue, $7.74 in food and beverage — proof AMC can still extract more money per seat even when the seat count doesn't grow. Pricing power isn't fake.

But here's the tension the bulls keep glossing over: operating leverage is a story about the income statement. Dilution is a story about the balance sheet. And right now the balance sheet story is winning by a landslide. AMC is fixing its books the same way it always has — not through free cash flow, not through debt paydown from operations, but by minting new shares and selling them into whatever demand retail traders and momentum funds are willing to provide. Roughly $4 billion in debt still sits on the books. Q3 2025 delivered a 24% EBITDA decline and a $298 million net loss, partly from refinancing charges — a reminder that even when the theater business behaves, the capital structure bites back.

The stock's own recent price action tells you everything about who's actually driving it. A +7.22% pop on July 14, a -6.28% drop on July 17 — that's not a company being re-rated on fundamentals, that's a crowd of traders reacting to headlines and vibes in real time. AMC remains one of the most-discussed retail names on the board, short interest is still elevated enough that squeeze chatter never fully dies, and every one of these swings is a reminder that this stock trades on narrative velocity, not discounted cash flow.

And the professionals who are paid to model this thing aren't exactly frothing at the mouth. B. Riley bumped its target to $2.25 off better May box office data — an upgrade, sure, but to a price that still screams "single-digit stock forever." TradersQuant's 12-month scenario work is the more honest gut-check: base case $1.64, bull case $2.79, bear case $0.83. Read that bear number again. Even the analysts who like the story are penciling in a floor near a buck.

So where does that leave us heading into the next few weeks? The September 24 Annual Meeting in Leawood is worth circling — there's a proposal to declassify the board, which is a real governance shift, not just proxy-season theater, and it'll pull some attention back to the stock ahead of it (paper-proxy requests are due September 11, for anyone keeping score on the calendar). After that, the next real fundamental test is the Q3 print, expected around November 11 — and that's the one that'll tell us whether the operating-leverage story has legs into the fall box office slate or whether it was a one-quarter sugar high.

Here's the honest take: AMC is a company where the operations are genuinely getting better and the capital structure is genuinely getting worse, at the same time, on purpose. Management is using every point of operating improvement to justify raising more equity rather than to build a cushion for shareholders. That's a rational survival strategy for the company. It is not the same thing as a rational investment thesis for you. Trade the volatility if that's your game — the swings are real and the retail crowd isn't going anywhere. But don't confuse a better income statement with a healed balance sheet. AMC isn't being cured. It's being managed, one dilutive raise at a time.